Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Details
Account Type
CFD Trading: MetaTrader 5
CFD Trading: MetaTrader 5
Investing: Web
Commission
0.1%
Trading schedule (UTC)
Open NowClosed NowCloses onOpening on
at
-
This shows the opening hours in your local time zone
(UTC)
Open an account and start investing with Metadoro now. Invite friends and get rewarded for their active trading. You can learn more about the affiliate program in your personal account.
Thank you for visiting metadoro.com. This website is managed by RHC Investments, which is authorised and regulated as an Investment Dealer by the Financial Services Commission of Mauritius with License number C115015381. Mauritius is not part of the European regulatory framework and is not in scope of (among others) the Markets in Financial Instruments Directive (MiFID) II.
By continuing you confirm that the decision is made independently and at your own exclusive initiative and that no solicitation or recommendation has been made by RHC Investments.
Create a NewsletterCreate a Newsletter
Customize your subscriptions the way you want!
Analytics
Get notified upon new posts
Select category
Price alerts
Discover timely market up-and-downs, pumps, etc.
Select category
Alert method
All categoriescategoriesAll instrumentsinstrumentssearchNothing found